The Population Impact Of Human Papillomavirus Vaccination On Circulating Genotypes
Funder
National Health and Medical Research Council
Funding Amount
$249,259.00
Summary
Infection with human papillomavirus (HPV) is very common. Persistent infection can cause abnormal changes to cervical cells as found on Pap smears and if untreated, over time can develop into cervical cancer. Recently, a vaccine was introduced in Australia for women aged 12-26. To monitor the effectiveness of this vaccine, young women aged 18-22 will be asked to self-collect a sample for HPV detection which will determine if HPV types targeted by vaccine are reducing in prevalence.
Non-viral Vectors For Targeted Delivery Of RNAi Nucleotides To Cervical Cancers
Funder
National Health and Medical Research Council
Funding Amount
$415,738.00
Summary
RNA interference (or gene silencing) is a new technique whereby we are able to turn off the expression of a particular gene either temporarily or permanently. Cancer is basically a genetic disease where certain protective genes are lost or cancer-causing genes expressed. Gene silencing holds great promise in the treatment of genetic disorders, infectious diseases and cancer. Cervical cancer is caused by infection with the human papillomavirus and the expression of two cancer-causing genes. Using ....RNA interference (or gene silencing) is a new technique whereby we are able to turn off the expression of a particular gene either temporarily or permanently. Cancer is basically a genetic disease where certain protective genes are lost or cancer-causing genes expressed. Gene silencing holds great promise in the treatment of genetic disorders, infectious diseases and cancer. Cervical cancer is caused by infection with the human papillomavirus and the expression of two cancer-causing genes. Using RNA interference we can turn off the expression of these two genes which results in the death of the cancer cell. We are also able to cure mice of tumours derived from human cervical cancer. The major issue with gene silencing is how to deliver it effectively to patients. Here we are investigating novel nanoparticulate systems to deliver this new gene-inhibiting drugs preferentially to the tumour site.Read moreRead less
HPV And Cervical Carcinoma: Signaling And Clinical Responses To Interferons
Funder
National Health and Medical Research Council
Funding Amount
$534,480.00
Summary
Cervical carcinoma and its treatment continues to be an important health concern in Australia. The interferons comprise an elaborate system of natural substances produced in the body, one of whose functions is to prevent cancer cells from developing. The interferons have been widely used to treat human diseases including viral infections and cancers caused by the wart virus. However, results of recent work indicates that viruses like the wart virus, HPV, have developed ways of inhibiting its eff ....Cervical carcinoma and its treatment continues to be an important health concern in Australia. The interferons comprise an elaborate system of natural substances produced in the body, one of whose functions is to prevent cancer cells from developing. The interferons have been widely used to treat human diseases including viral infections and cancers caused by the wart virus. However, results of recent work indicates that viruses like the wart virus, HPV, have developed ways of inhibiting its effectiveness. We have found that cervical carcinoma cells and virally infected cells resist the direct anti-cancer and anti-viral effects of interferons because they have abnormalities in their ability to respond to interferon. We have made good progress in understanding why these cells do not respond to the interferons. In particular they show a deficiency in the activity of cell proteins required to transmit the interferon signal inside the cells. The current proposal will allow us to gain a greater understanding of the processes inside cells that are taken over by the wart viral proteins and the reasons for its abnormality in interferon resistant cancer cells. We will determine whether the levels of certain genes in clinical samples from patients relates to their response to interferon treatment. This may allow us to establish a test to predict which patients will respond to interferon therapy, saving patients from ineffective treatment, side effects and cost. This study will have a broad significance to many human diseases where abnormalities in interferon signaling occur and will help to bring about the necessary changes in cell properties to overcome the abnormalities, restore the responses and improve the application of interferons to treat infectious diseases and perhaps other cancers as well.Read moreRead less
An Epidemic Of Vulvar Cancer In Young Women: Investigating The Role Of Human Papillomavirus And Genetic Susceptibility
Funder
National Health and Medical Research Council
Funding Amount
$489,706.00
Summary
Vulvar cancer is a rare disease; in 1993-1997 the age-adjusted incidence rate in Australia was 1.4 per 100,000 women (average 207 cases per year), similar to the incidence in most other countries. An epidemic of cases of vulvar cancer has been identified in younger Indigenous women living in remote communities in the Northern Territory (NT). Vulvar cancer is over fifty times more common in women aged less than 50 years in these communities than in the total Australian population. Women in these ....Vulvar cancer is a rare disease; in 1993-1997 the age-adjusted incidence rate in Australia was 1.4 per 100,000 women (average 207 cases per year), similar to the incidence in most other countries. An epidemic of cases of vulvar cancer has been identified in younger Indigenous women living in remote communities in the Northern Territory (NT). Vulvar cancer is over fifty times more common in women aged less than 50 years in these communities than in the total Australian population. Women in these communities also experience higher rates of high-grade Vulvar Intraepithelial Neoplasia (a pre-cursor to vulvar cancer), than elsewhere in the NT. Vulvar cancer is usually much more common in older women than younger women. In young women vulvar cancer and VIN are thought to be caused by infection with cancer causing strains of human papillomavirus (HPV), particularly the strain known as HPV16. In older women, vulvar cancer is not caused by HPV. In the remote communities in the NT, vulvar cancer is occurring almost entirely in young women, the amount of cancer occurring in older women in these communities is similar to the amount expected in the total Australian population. This project will investigate the cause of this epidemic of vulvar cancer and high-grade VIN. It will investigate whether HPV16 is more prevalent in these communities than elsewhere in Australia; whether there is a variant strain of HPV16 in these communites that is more virulent at causing cancer, and whether the disease occurs more commonly in families, which would mean that women in these communities inherit an increased susceptibility to vulvar cancer and VIN. This project will help to increase our understanding of vulvar cancer and VIN, help to control this epidemic, and inform whether the new HPV vaccines may be effective in preventing vulvar cancer in these communities.Read moreRead less
Optimising Immunity Towards Cancers By Vaccination.
Funder
National Health and Medical Research Council
Funding Amount
$211,320.00
Summary
In this project we will be studying the mechanisms of how an efficient anti cancer vaccine could be generated. We will be using cervical cancer associated human papillomavirus type 16 E7 protein as the model protein in an experimental vaccine model in mice. The results obtained from this project not only able us to design better vaccines against cervical cancers in women but against many other cancers and viruses.
Centre For Research Excellence In Cervical Cancer Control (C4)
Funder
National Health and Medical Research Council
Funding Amount
$2,486,383.00
Summary
Cervical cancer remains common globally despite over 50 years of Pap testing. Australia led the world in HPV vaccination and in 2017 will be the first to deliver a national screening program based on HPV testing. Our CRE, led by cervical cancer prevention experts at CCNSW,VCS, and Kirby, will marry cross-disciplinary research and evaluation of HPV vaccination and screening to provide solid evidence about these new approaches with a view to ultimately reducing the global burden of this cancer.
Effectiveness And Cost-Effectiveness Of HPV Vaccination And HPV-Based Cervical Cancer Screening Strategies In China
Funder
National Health and Medical Research Council
Funding Amount
$420,692.00
Summary
In the absence of preventative initiatives, up to 187,000 women will develop cervical cancer in China every year. However, the disease is preventable using human papillomavirus (HPV) vaccination and primary HPV screening. Building on previous work, we will evaluate the most effective and cost-effective options for cervical cancer prevention, in order to provide an comprehensive evidence base for China’s health decision-makers.
Optimising Cervical Screening After The Introduction Of HPV Vaccination In Australia: Modelling Of Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$316,089.00
Summary
This research project will aid decision-making about how best to perform cervical screening in Australia after the introduction of vaccination against the human papillomavirus (or HPV). The project will use computer simulation techniques to explore different scenarios for vaccination and screening and to determine the optimal approach. This project involves a group of international collaborators with expertise in a number of areas including cancer epidemiology, screening for cancer, and computer ....This research project will aid decision-making about how best to perform cervical screening in Australia after the introduction of vaccination against the human papillomavirus (or HPV). The project will use computer simulation techniques to explore different scenarios for vaccination and screening and to determine the optimal approach. This project involves a group of international collaborators with expertise in a number of areas including cancer epidemiology, screening for cancer, and computer simulation methods. HPV is the virus responsible for the development of cervical cancer, and clinical trials have demonstrated that HPV vaccines administered to adoloescent girls are very effective at preventing disease that might have led to cancer in the future. However, Australia currently has a very effective Pap smear screening program, and in the first phase after the introduction of vaccination it will be important for women to continue being screened as usual. In the long term, HPV vaccination is expected to reduce the need for Pap smears. The research will involve a very detailed simulation of how HPV is transmitted in the Australian population, and how this will change after vaccination. The simulation will address questions of importance for any future public HPV vaccination program, such as whether males should be vaccinated as well as females. The simulation will also be used to determine the optimal starting age and frequency of Pap smears in the future. The outcomes of the research will be very important for policy-makers. In the long term, this research will ensure that the best recommendations are formulated for the timing and frequency of Pap smears after HPV vaccination is introduced.Read moreRead less
The Human Papilloma Virus Oncoprotein E7 Degrades The Retinoblastoma Protein By Enhancing Calpain Activity
Funder
National Health and Medical Research Council
Funding Amount
$258,067.00
Summary
Cervical cancer is the second most prevalent cancer worldwide and the fifth leading cause of cancer deaths in women. Approximately 470,000 new cases are diagnosed annually. In most cases cervical cancer is thought to be caused by certain types of the human papillomavirus. Human papillomavirus makes a seies of proteins that cause the destruction of key host proteins in the cells they infect. This destruction is central to the formation of cervical cancer. We have recently discovered that we can p ....Cervical cancer is the second most prevalent cancer worldwide and the fifth leading cause of cancer deaths in women. Approximately 470,000 new cases are diagnosed annually. In most cases cervical cancer is thought to be caused by certain types of the human papillomavirus. Human papillomavirus makes a seies of proteins that cause the destruction of key host proteins in the cells they infect. This destruction is central to the formation of cervical cancer. We have recently discovered that we can prevent this destruction and rescue the key host proteins using inhibitors of the enzyme calpain. Here we seek to determine whether calpain inhibitors could find application in the treatment of human papillomavirus associated cancer.Read moreRead less